Seminars in Oncology
Volume 35, Supplement 3 , Pages S28-S33, June 2008

Pharmacokinetics, Metabolites, and Preclinical Safety of Vinflunine

  • Sharon Lobert

      Affiliations

    • University of Mississippi Medical Center, Jackson, MS.
  • ,
  • Christian Puozzo

      Affiliations

    • Institut de Recherche Pierre Fabre, Castres, France.
    • Corresponding Author InformationAddress correspondence to Christian Puozzo, PhD, Oncology Pharmacokinetic Department, Institut de Recherche Pierre Fabre, 2 rue Christian d'Espic, 81106 Castres, France

The novel microtubule inhibitor, vinflunine, has a unique mechanism of action that differs from other members of the vinca alkaloid class in terms of tubulin-binding affinity, microtubule dynamics, spiral formation, and intracellular accumulation. Vinflunine has shown significant activity in vivo, which involves its antimitotic, antiangiogenic, and antivascular properties. The promising preclinical activity of vinflunine has warranted further investigation in the clinical setting. This review explores the distinct interaction of vinflunine with its intracellular targets to gain insight into its mechanism of action and safety profile. The pharmacokinetic properties and metabolism of vinflunine in animals and in human subjects are also discussed, together with an analysis of potential drug-drug interactions and the influence of age, liver dysfunction, or renal dysfunction on the overall activity of vinflunine.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr Lobert has received consulting fees from Bristol-Myers Squibb and has received research support from Pierre Fabre Oncologie. Dr Puozzo is an employee of the Institut de Recherche Pierre Fabre, a private pharmaceutical company supporting the development of vinflunine.

PII: S0093-7754(08)00020-1

doi:10.1053/j.seminoncol.2008.01.007

Seminars in Oncology
Volume 35, Supplement 3 , Pages S28-S33, June 2008